The Impact of Drug Interactions with Tyrosine Kinase Inhibitors on Adverse Event Development based on the changes of drug concentration level: Meta-analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience. However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA provides some guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted to understand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions: Study finds TKI-DDI not significantly linked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development
Abstract
Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience. However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA provides some guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted to understand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions: Study finds TKI-DDI not significantly linked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development
참고문헌 (24)
- Prasad V, "The high price of anticancer drugs : Origins, implications, barriers, solutions", Nat Rev Clin Oncol, 14(6), pp.381~390 (2017)
- Rogala BG, "Oral anticancer therapy : Management of drug interactions", Journal of Oncology Practice, 15(2), pp.81~90 (2019)
- Das A, "Dermatological adverse drug reactions to tyrosine kinase inhibitors : a narrative review", Clin Exp Dermatol, 48(6), pp.599~608 (2023)
- Huang L, "Tyrosine kinase inhibitors for solid tumors in the past 20 years(2001-2020)", Journal of Hematology & Oncology, 13(1), pp.143~ (2020)
- Ismail M, "Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy", BMC cancer, 20(1), pp.335~ (2020)
- Wang H, "Potentially hazardous drug-drug interactions associated with oral antineoplastic agents prescribed in chinese tertiary care teaching hospital settings : A multicenter cross-sectional study", Frontiers in pharmacology, 13, pp.808848~ (2022)
- Sudsakorn S, "2020 fda drug-drug interaction guidance : A comparison analysis and action plan by pharmaceutical industrial scientists", Current Drug Metabolism, 21(6), pp.403~426 (2020)
- Deodhar M, "Mechanisms of cyp450 inhibition : Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice", Pharmaceutics, 12(9), pp.846~ (2020)
- Page MJ, "The prisma 2020 statement : An updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- Higgins JP, "The cochrane collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Poggesi I, "Effect of fluconazole and itraconazole on the pharmacokinetics of erdafitinib in healthy adults : A randomized, open-label, drug-drug interaction study", Eur J Drug Metab Pharmacokinet, 45(1), pp.101~111 (2020)
- Abbas R, "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects", Br J Clin Pharmacol, 71(4), pp.522~527 (2011)
- Martin P, "Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole", Drugs R D, 11(1), pp.37~51 (2011)
- Dutreix C, "Pharmacokinetic interaction between ketoconazole and imatinib mesylate(glivec)in healthy subjects", Chemother Pharmacol, 54(4), pp.290~294 (2004)
- Dymond AW, "Effects of cytochrome p450(cyp3a4 and cyp2c19)inhibition and induction on the exposure of selumetinib, a mek1", 2 inhibitor, in healthy subjects : Results from two clinical trials, 2017, pp.73(2), 175~184
- Pithavala YK, "Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers", Invest New Drugs, 30(1), pp.273~281 (2012)
- Shumaker R, "Effects of ketoconazole on the pharmacokinetics of lenvatinib(e7080)in healthy participants", Clin Pharmacol Drug Dev, 4(2), pp.155~160 (2015)
- Liu Y, "Multiple administrations of itraconazole increase plasma exposure to pyrotinib in chinese healthy adults", Drug Des Devel Ther, 15, pp.2485~2493 (2021)
- Abbas R, "Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects", J Clin Pharmacol, 51(12), pp.1721~1727 (2011)
- Narasimhan NI, "Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects", J Clin Pharmacol, 53(9), pp.974~981 (2013)
- Li J, "Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FIT3 inhibitor, and its active metabolite", Br J Clin Pharmacol, 85(9), pp.2108~2117 (2019)
- Ke AB, "Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies", Clin Pharmacol Ther, 95(5), pp.473~476 (2014)
- Tornio A, "Clinical studies on drug-drug interactions involving metabolism and transport : Methodology, pitfalls, and interpretation", Clin Pharmacol Ther, 105(6), pp.1345~1361 (2019)
- Liu L, "Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies", J Clin Pharmacol, 56(2), pp.143~151 (2016)